About: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.43 (-1.22%)
NRSN NASDAQ Neurosense Therapeutics Ltd
Neurosense Therapeutics Ltd share price
Atividade de preço de NRSN
Último preço
$ 2,330
Variação (24h)
-0,13 USD (5,28%)
Volume
29.68K
Volume (média 4 sem.)
-
Abertura
$ 2,47
Variação do dia
$ 2,31 - $ 2,75
Fechamento anterior
$ 2,46
Último negócio
26 Oct, 8:00 pm GMT+0
Atrasado
26 Oct, 8:00 pm GMT+0
NRSN price performance
Atrasado
26 Oct, 8:00 pm GMT+0
quote.marketSignals